Opinion

Video

Unmet Needs in oHCM Care

An expert cardiologist examines unmet needs and bridging the gap in care for patients with oHCM.

This is a video synopsis of a discussion involving James L. Januzzi, MD, who addresses the unmet needs of patients with obstructive hypertrophic cardiomyopathy (HCM). While advancements have been made in recognizing the risk for major adverse cardiovascular events, such as arrhythmia or sudden death, individuals with HCM still face challenges.

The obstruction of the left ventricular outflow tract creates a gradient, leading to systolic anterior motion of the mitral valve, mitral regurgitation, and impaired relaxation of the heart muscle. Current medical therapies, including calcium channel blockers, beta blockers, and disopyramide, often fail to adequately address these issues, leaving room for improvement in managing symptoms and enhancing quality of life.

Despite a normal lifespan, individuals with HCM may experience reduced exercise capacity and compromised health status. Invasive treatments, such as surgical septal reduction or catheter-based approaches, offer effective solutions but are irreversible and carry inherent risks.

The ultimate goal is to enhance background medical therapy to potentially reduce the need for invasive procedures and identify the most suitable candidates for such interventions. Moreover, there is a growing interest in developing therapies that not only alleviate symptoms in the short term but also alter the disease trajectory in the long run, reducing the risk of arrhythmias and other complications associated with HCM.

In summary, while current interventions provide some relief, there remains a need for further advancements in medical management to address the multifaceted challenges faced by individuals with obstructive HCM.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.

Related Videos
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
© 2024 MJH Life Sciences

All rights reserved.